We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

Is Compounded Semaglutide Still Available in 2026?

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded GLP-1 medications are not the same as brand-name products and may differ in formulation, purity, and potency.

If you have been searching to find out whether compounded semaglutide is still available, coming back, or banned in 2026, here is the honest short answer. As of October 16, 2026, semaglutide and tirzepatide are not on FDA’s drug shortage list, and FDA’s grace periods for shortage-based compounding ended in 2025[2]. Federal law still allows state-licensed pharmacies to compound a drug for an individual patient within limits[6], and some telehealth programs still offer compounded GLP-1 medications. Continued availability is not guaranteed. That means it is reasonable to understand what changed and have a plan rather than waiting and worrying.

The short answer

Yes, for now, some telehealth programs still offer compounded GLP-1 medications, and a licensed provider may prescribe one when it is appropriate for you. No, that access is not promised to last, and no, FDA has not announced a categorical ban.

If you are reading this because you saw a headline about the FDA and compounded GLP-1, take a breath. The situation is more specific than “it is gone.” What actually happened is a change in the legal basis for large-scale compounding, not a switch being flipped off overnight. Some pharmacies have stepped back, others continue, and the practical answer to “can I still get it” depends on the pharmacy, your state, and a provider’s evaluation of your health history.

The rest of this page walks through what changed, what it means for availability right now, how the process works at most programs, and what to do if access gets harder later.

What changed: the end of the shortage

Compounded GLP-1 medications became widely available because of a specific situation. When demand for semaglutide and tirzepatide outpaced supply, the FDA listed them on its drug shortage list. While a drug is on that list, federal law allows broader compounding of it, including by outsourcing facilities using bulk drug substance[2][7].

Then FDA determined both shortages were resolved. Here are the dates FDA published[2]:

  • Tirzepatide. FDA first determined the tirzepatide injection shortage was resolved on October 2, 2024, re-evaluated that decision, and reissued it on December 19, 2024. For state-licensed (503A) pharmacies, FDA’s enforcement discretion for shortage-based compounding ended after a federal court denied a preliminary injunction on March 5, 2025. For outsourcing facilities (503B), it ended on March 19, 2025.
  • Semaglutide. FDA determined the semaglutide injection shortage was resolved on February 21, 2025. For 503A pharmacies, enforcement discretion ended after April 22, 2025 (a federal court denied a preliminary injunction on April 24, 2025). For 503B outsourcing facilities, it ended on May 22, 2025.
  • Status as of October 16, 2026. FDA’s drug shortage database lists both the semaglutide injection and tirzepatide injection shortages as resolved[3][4]. FDA’s compounding statement, most recently updated April 1, 2026, says tirzepatide and semaglutide “do not currently appear on the 503B bulks list or on FDA’s drug shortage list”[2].

This is the part that gets compressed into scary headlines. The shortage ending is real, and it changed the rules. But “the rules changed” is not the same as “every compounded GLP-1 is now prohibited.” For the full legal picture, including the difference between 503A and 503B pharmacies, see our guide on compounded GLP-1 after the shortage. This page stays focused on the practical question, and none of it is legal advice.

What that means for availability right now

Here is the practical picture as of October 16, 2026.

State-licensed pharmacies (section 503A). Federal law allows a state-licensed pharmacy to compound a drug for an individual patient based on a prescription[6]. One condition is that the pharmacy may not compound, “regularly or in inordinate amounts,” drugs that are essentially copies of a commercially available drug[2][6]. Under the statute, a compounded drug is not “essentially a copy” when a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner[6]. FDA’s April 1, 2026 update reminds compounders of these conditions[2].

Outsourcing facilities (section 503B). Outsourcing facilities generally may not compound from bulk drug substance unless the substance is on FDA’s 503B bulks list or the drug is on FDA’s drug shortage list[2][7]. As noted above, FDA says neither semaglutide nor tirzepatide currently appears on either list.

At the same time, availability is uneven. It varies by pharmacy and by state. Some compounders have stopped preparing GLP-1 medications entirely. Others continue. State pharmacy boards, federal guidance, and ongoing legal questions are all part of the picture, and they are not all moving in the same direction at the same speed. The honest way to describe it is that the market is fragmenting rather than holding steady.

What that means for you is simple. You cannot assume that what one person could get six months ago in one state is what you can get today in yours. Ask any program you are considering which pharmacy prepares the medication and whether it is a state-licensed pharmacy or an FDA-registered outsourcing facility, and expect a licensed provider to decide whether a prescription is appropriate for you.

Can you still start today?

Some telehealth programs still offer compounded GLP-1 medications as of October 16, 2026. At most of them, the process is built around a licensed provider making the clinical call, not a checkout button.

Here is how it usually works:

  • You complete an online form covering your health history, current medications, and goals.
  • A licensed provider reviews your information and decides whether a prescription is medically appropriate for you. A prescription is never guaranteed, and the provider may decide it is not right for you.
  • If a prescription is appropriate, a state-licensed compounding pharmacy prepares the medication and it is usually shipped to you. Ask whether follow-up visits, lab work, and any coaching are included or cost extra.
  • Telehealth rules vary by state, and some programs require a live video visit before prescribing in certain states. Ask the program how it handles your state and whether the provider is licensed where you live.

The provider’s evaluation should be genuine, not a formality. You can read more about how an online evaluation works in the guide to getting a GLP-1 prescription online.

Transformation Health does not accept payment from providers. How we make money.

What to do if it becomes harder to get later

Because continued availability is not something anyone can honestly promise, the smart move is to understand your backup options now, before you need them. If compounded access becomes harder where you live, you are not out of choices.

Start by talking with the provider you choose. They can tell you what is currently available and help you think through what makes sense for your situation if your current option changes. This is exactly the kind of conversation an ongoing provider relationship is for.

Ask before changing your dose. If you are already taking a GLP-1 medication, do not change your dose or schedule on your own. Whether a different dose or schedule fits your situation is a decision for your prescriber.

Be aware of brand-name routes as a backup. Some insurance plans cover brand-name GLP-1 medications for weight management, not only for diabetes or cardiovascular indications, and coverage varies by plan. Manufacturers also run self-pay programs, and manufacturer patient-assistance programs may help if you income-qualify. Our overview of savings and assistance programs walks through these paths.

None of these is a perfect substitute for everyone, and we are not telling you that compounded GLP-1 is interchangeable with a brand-name product. The point is that having a plan beats being caught off guard.

What to check before using compounded GLP-1 medication

If you are considering a compounded GLP-1 medication, these checks come from FDA’s own guidance and warnings.

  • A real prescription. A licensed provider should evaluate you before any medication is prescribed. A site that sells semaglutide or tirzepatide with no prescription is a red flag.
  • A licensed pharmacy. The medication should come from a state-licensed pharmacy (you can check its license with the state board of pharmacy) or an FDA-registered outsourcing facility, which you can look up on FDA’s list of registered outsourcing facilities[8]. The guide to 503A vs 503B pharmacies explains the difference.
  • The form of the active ingredient. FDA has warned that semaglutide sodium and semaglutide acetate are different active ingredients from those used in the approved drugs, and says it is not aware of any lawful basis for their use in compounding[5]. Ask which form the pharmacy uses.
  • No “research use” products. FDA has warned companies selling semaglutide, tirzepatide, and other GLP-1 products labeled “not for human consumption” or for research use, and urges consumers not to buy them[5].
  • Clear dosing instructions. FDA has received adverse event reports, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide, including patients measuring incorrect doses[5]. Ask how your dose is measured and who to contact with questions.
  • Honesty about the rules. Be cautious with any program that promises compounded GLP-1 will be available indefinitely. No one can promise that. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy laws, which may change.

We re-check this page when FDA updates its compounding policy. It was last reviewed on October 16, 2026. For more on what separates a safe source from a risky one, read how to choose a safe compounding pharmacy.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Important disclosures

This content is for general education and is not medical advice or legal advice. Talk with a licensed provider about your situation.

Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality[1]. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Nothing on this page should be read as claiming they are equivalent.

Regulatory status can change. The status described on this page is as of October 16, 2026, based on FDA’s compounding statement (most recently updated April 1, 2026) and FDA’s drug shortage database[2][3][4]. Check the FDA pages for the current statement. Availability cannot be guaranteed.

Individual results vary, and weight loss is not guaranteed.

Citations

[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality.)

[2] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: tirzepatide and semaglutide shortage resolution dates, 503A and 503B enforcement discretion end dates, March 5, 2025 and April 24, 2025 court rulings, 503A and 503B conditions, bulks list and shortage list status.)

[3] U.S. Food and Drug Administration. “FDA Drug Shortages: Semaglutide Injection.” Status: Resolved. Accessed 2026-10-16. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r

[4] U.S. Food and Drug Administration. “FDA Drug Shortages: Tirzepatide Injection.” Status: Resolved. Accessed 2026-10-16. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r

[5] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: salt-form warning, research-use products, dosing-error reports.)

[6] 21 U.S.C. 353a, Pharmacy compounding (section 503A of the Federal Food, Drug, and Cosmetic Act). https://www.law.cornell.edu/uscode/text/21/353a (Accessed 2026-10-16. Supports: compounding for an identified individual patient based on a prescription; “essentially a copy” limit and definition.)

[7] 21 U.S.C. 353b, Outsourcing facilities (section 503B of the Federal Food, Drug, and Cosmetic Act). https://www.law.cornell.edu/uscode/text/21/353b (Accessed 2026-10-16. Supports: bulk drug substance restrictions for outsourcing facilities.)

[8] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16.)

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Results vary. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Status on this page is as of October 16, 2026. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Is compounded semaglutide still available in 2026?
As of October 16, 2026, semaglutide is not on FDA's drug shortage list. FDA determined on February 21, 2025 that the semaglutide injection shortage was resolved, and its enforcement discretion periods for shortage-based compounding ended in 2025. Federal law still allows a state-licensed pharmacy to compound a drug for an individual patient based on a prescription, within limits, including a limit on regularly compounding drugs that are essentially copies of a commercially available drug. Some telehealth programs still offer compounded semaglutide, and availability varies by pharmacy and by state. A licensed provider decides whether any prescription is appropriate. Compounded semaglutide is not FDA-approved.
Is compounded tirzepatide still available in 2026?
As of October 16, 2026, tirzepatide is not on FDA's drug shortage list. FDA reissued its decision that the tirzepatide injection shortage was resolved on December 19, 2024, and its enforcement discretion periods for shortage-based compounding ended in March 2025. The same federal limits on compounding for individual patients apply. Some programs still offer compounded tirzepatide and some compounders have stopped preparing it. A licensed provider decides whether a prescription is appropriate. Compounded tirzepatide is not FDA-approved.
Did the FDA ban compounded GLP-1?
FDA has not announced a categorical ban. What changed is shortage status. FDA determined that the tirzepatide and semaglutide shortages were resolved, and as of its April 1, 2026 update FDA states that the two drugs do not currently appear on the 503B bulks list or on its drug shortage list. That restricts outsourcing facilities from compounding them from bulk drug substance. State-licensed pharmacies may still compound for individual patients when the conditions in section 503A of the federal Food, Drug, and Cosmetic Act are met. Our guide on compounded GLP-1 after the shortage covers the legal picture in more detail. This is general information, not legal advice.
Can I still start a compounded GLP-1 program today?
Some telehealth programs still offer compounded GLP-1 medications as of October 16, 2026. At most programs, you complete an online health history and a licensed provider reviews it and decides whether a prescription is appropriate. A prescription is never guaranteed. Before you pay, ask which pharmacy prepares the medication, whether it is a state-licensed pharmacy or an FDA-registered outsourcing facility, and which form of the active ingredient it uses. Telehealth rules vary by state, so ask how the program handles yours.
What happens if compounded GLP-1 becomes unavailable later?
If access becomes harder, the provider you choose can explain your options. Those may include brand-name GLP-1 medications through insurance, manufacturer self-pay programs, and manufacturer patient-assistance programs for people who qualify. Do not change your dose or schedule on your own; that is a decision for your prescriber. The right path depends on your situation, which is why it helps to understand your options before you need them.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.